Tracking the sequencing platform transition.
The Roche Axelios launch is the most consequential event in sequencing since NovaSeq X. Right now, no one has good data on actual adoption.
ReadDepth is a community-tracked dataset of who runs what, who's evaluating, who's budgeted, and who's watching. AI-personalized reports for every contributor. Aggregate findings shared publicly.
Founding Contributor program — limited
17 of 500 founders enrolled
483 slots remaining. Founders get lifetime free access to the Pro tier while they remain active contributors.
~90 seconds. No login. Aggregate findings free; institution-level data in paid tiers later this year.